RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy

Wang, Guowen; Wang, Zuyi; Li, Chuankui; Duan, Guixin; Wang, Kangwu; Li, Qicai; Tao, Tao

doi:10.1016/j.biopha.2018.06.137

Cited by 99 publications

(47 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 Therefore, various nanoparticles including polymeric nanoparticles, lipid nanoparticles, dendrimers, and micelles have been designed to encapsulate anticancer drugs. 8 Lipid-polymer hybrid nanoparticles (LPNs) usually contained a polymer inner core and a phospholipid surface layer. 9 LPNs combine advantages of both liposomes and polymers into a single platform, which is an ideal system for combinatorial delivery based on the dual-component structure.…”

Section: Introductionmentioning

confidence: 99%

Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles

Wang¹

2020

DDDT

View full text Add to dashboard Cite

Purpose: Cervical cancer is one of the most common causes of death among women globally. Combinations of cisplatin, paclitaxel, bevacizumab, carboplatin, topotecan, and gemcitabine are recommended as first-line therapies. Methods: This study focuses on the development of folate-decorated, pH-sensitive lipidpolymer hybrid nanoparticles (LPNs). Loading carboplatin (CBP) and paclitaxel (PTX), LPNs were expected to combine the therapeutic effects of CBP and PTX, thus show synergistic ability on cervical cancer. Results: FA-CBP/PTX-LPNs showed the sizes of 169.9 ± 5.6 nm, with a narrow size distribution of 0.151 ± 0.023. FA-CBP/PTX-LPNs exhibited pH-responsive drug release, high cellular uptake efficiency (66.7 ± 3.1%), and prominent cell inhibition capacity (23 ± 1.1%). In vivo tumor distribution and tumor inhibition efficiency of FA-CBP/PTX-LPNs was the highest, with no obvious body weight lost. Conclusion: High tumor distribution and remarkable antitumor efficiency obtained using in vitro as well as in vivo models further proved the FA-CBP/PTX-LPNs is a promising tool for cervical cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles

Wang¹

2020

DDDT

View full text Add to dashboard Cite

show abstract

“…The above HCC tumor tumor-bearing mice which injected with samples were sacrificed by cervical dislocation on days 7, 14, 21 and the blood were collected into heparinized tubes. 48 Blood samples were centrifuged (15,000 rpm for 20 min at 4°C) to isolate plasma and assayed for the alanine transaminase (ALT), creatine phosphokinase (CPK), and lactate dehydrogenase (LDH).…”

Section: In Vivo Tolerance Analysismentioning

confidence: 99%

Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles

Bian¹,

Guo²

2020

DDDT

View full text Add to dashboard Cite

Purpose: Hepatocellular carcinoma (HCC) is a leading cancer worldwide. In the present investigation, sorafenib (SFN) and curcumin (CCM) were co-delivered using pH-sensitive lactosylated nanoparticles (LAC-NPs) for targeted HCC treatment. Methods: pH-responsive lactosylated materials were synthesized. SFN and CCM codelivered, pH-responsive lactosylated nanoparticles (LAC-SFN/CCM-NPs) were selfassembled by using the nanoprecipitation technique. The nanoparticles were characterized in terms of particle size, charge and drug release profile. The anti-cancer effects of the nanoparticles were evaluated in human hepatic carcinoma cells (HepG2) cells and HCC tumor xenograft models. Results: LAC-SFN/CCM-NPs are spherical particles with light coats on the surface. The size and zeta potential of LAC-SFN/CCM-NPs were 115.5 ± 3.6 nm and −34.6 ± 2.4, respectively. The drug release of LAC-SFN/CCM-NPs in pH 5.5 was more efficient than in pH 7.4. LAC-SFN/CCM-NPs group exhibited the smallest tumor volume (239 ± 14 mm 3 ), and the inhibition rate of LAC-SFN/CCM-NPs was 77.4%. Conclusion: In summary, LAC-SFN/CCM-NPs was proved to be a promising system for targeted HCC therapy.

show abstract

“…Several studies used integrin-targeted NPs and loaded them with two different therapeutic agents. For example, some researchers loaded topotecan (TPT) and quercetin (QT) on mesoporous silica NPs for the treatment of integrin-expressing breast cancer cells [171], another group loaded paclitaxel and cisplatin onto RGD-conjugated lipid-polymer NPs for the treatment of lung tumor [172], and another study combined doxorubicin with c-Myc small interfering RNA (siRNA) and loaded these onto RGD-conjugated NPs [173]. These new-generation NP-based drugs provide a promising future for improving chemotherapy.…”

Section: Drug Deliverymentioning

confidence: 99%

Targeting Integrins in Cancer Nanomedicine: Applications in Cancer Diagnosis and Therapy

Opadele

Onodera

et al. 2019

Cancers

View full text Add to dashboard Cite

Due to advancements in nanotechnology, the application of nanosized materials (nanomaterials) in cancer diagnostics and therapeutics has become a leading area in cancer research. The decoration of nanomaterial surfaces with biological ligands is a major strategy for directing the actions of nanomaterials specifically to cancer cells. These ligands can bind to specific receptors on the cell surface and enable nanomaterials to actively target cancer cells. Integrins are one of the cell surface receptors that regulate the communication between cells and their microenvironment. Several integrins are overexpressed in many types of cancer cells and the tumor microvasculature and function in the mediation of various cellular events. Therefore, the surface modification of nanomaterials with integrin-specific ligands not only increases their binding affinity to cancer cells but also enhances the cellular uptake of nanomaterials through the intracellular trafficking of integrins. Moreover, the integrin-specific ligands themselves interfere with cancer migration and invasion by interacting with integrins, and this finding provides a novel direction for new treatment approaches in cancer nanomedicine. This article reviews the integrin-specific ligands that have been used in cancer nanomedicine and provides an overview of the recent progress in cancer diagnostics and therapeutic strategies involving the use of integrin-targeted nanomaterials.

show abstract

RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy

Cited by 99 publications

References 36 publications

<p>Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles</p>

<p>Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles</p>

<p>Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles</p>

Targeting Integrins in Cancer Nanomedicine: Applications in Cancer Diagnosis and Therapy

Contact Info

Product

Resources

About